Kodiak Sciences Inc

K27

Company Profile

  • Business description

    Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.

  • Contact

    1200 Page Mill Road
    Palo AltoCA94304
    USA

    T: +1 650 281-0850

    E: [email protected]

    https://www.kodiak.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    121

Stocks News & Analysis

stocks

Ask the analyst: Can this genius product create the next ASX software king?

Siteminder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
stocks

Impact of ANZ’s huge fine

Working to prevent repeated failures could also improve competitiveness.
stocks

Acquisition a sign of weakness for overvalued ASX share

Acquisition unlikely to improve prospects in the US and detracts from other opportunities.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,151.201.30-0.01%
CAC 407,886.2610.67-0.14%
DAX 4023,675.7673.10-0.31%
Dow JONES (US)45,883.4549.230.11%
FTSE 1009,255.7321.30-0.23%
HKSE26,438.518.05-0.03%
NASDAQ22,348.75207.640.94%
Nikkei 22544,902.27134.150.30%
NZX 50 Index13,234.8926.580.20%
S&P 5006,615.2830.990.47%
S&P/ASX 2008,877.703.00-0.03%
SSE Composite Index3,861.861.360.04%

Market Movers